These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33048389)

  • 1. Early changes in IL-21, IL-22, CCL2, and CCL4 serum cytokines after outpatient autologous transplantation for multiple sclerosis: A proof of concept study.
    Jaime-Pérez JC; Turrubiates-Hernández GA; López-Silva LJ; Salazar-Riojas R; Gómez-Almaguer D
    Clin Transplant; 2020 Dec; 34(12):e14114. PubMed ID: 33048389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation.
    Hendrawan K; Khoo MLM; Visweswaran M; Massey JC; Withers B; Sutton I; Ma DDF; Moore JJ
    Front Immunol; 2021; 12():782935. PubMed ID: 35126353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
    Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
    Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
    Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
    Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
    JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis.
    Kasarełło K; Snarski E; Sulejczak D; Ciesielski T; Wiśniewska A; Wrzesień R; Cudnoch-Jędrzejewska A
    Arch Immunol Ther Exp (Warsz); 2021 Jun; 69(1):17. PubMed ID: 34181099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The consequences of delayed diagnosis and treatment in persons with multiple sclerosis given autologous hematopoietic stem cell transplantation.
    Pastelín-Martínez ML; Gallardo-Pérez MM; Gómez-de-León A; Olivares-Gazca JC; Hernández-Flores EJ; Sánchez-Bonilla D; Montes-Robles M; Robles-Nasta M; Ocaña-Ramm G; Soto-Olvera S; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Diagnosis (Berl); 2024 May; 11(2):164-170. PubMed ID: 38230519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis.
    Helbig G; Widuchowska M; Koclęga A; Kopińska A; Kopeć-Mędrek M; Gaweł WB; Spałek A; Żak J; Grygoruk-Wiśniowska I; Liwoch R; Kucharz E; Markiewicz M
    Clin Rheumatol; 2018 Jun; 37(6):1709-1714. PubMed ID: 29256111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Zafeiri L; Åkerfeldt T; Tolf A; Carlson K; Skalkidou A; Burman J
    PLoS One; 2023; 18(4):e0284288. PubMed ID: 37043510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kartashov AV; Kurbatova KA; Gorodokin GI; Novik AA
    Exp Hematol; 2012 Nov; 40(11):892-8. PubMed ID: 22771495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
    Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
    Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.
    de Oliveira GL; Ferreira AF; Gasparotto EP; Kashima S; Covas DT; Guerreiro CT; Brum DG; Barreira AA; Voltarelli JC; Simões BP; Oliveira MC; de Castro FA; Malmegrim KC
    Clin Exp Immunol; 2017 Mar; 187(3):383-398. PubMed ID: 28008595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Bose G; Thebault S; Rush CA; Atkins HL; Freedman MS
    Mult Scler; 2021 Feb; 27(2):167-173. PubMed ID: 32364422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
    Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
    Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant.
    Jaime-Pérez JC; Gómez-Galaviz AC; Turrubiates-Hernández GA; Picón-Galindo E; Salazar-Riojas R; Méndez-Ramírez N; Gómez-Almaguer D
    Cytotherapy; 2020 Mar; 22(3):144-148. PubMed ID: 32057615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.